Related Experiment Video
Updated: May 29, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Farnesylation-driven KRAS phase separation promotes colon tumor growth
Xingwen Wang1, Yi Zhang1, Minqiao Lu1
1School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang 150001, China; Key Laboratory of Science and Engineering for the Multi-modal Prevention and Control of Major Chronic Diseases, Ministry of Industry and Information Technology, HIT Zhengzhou Research Institute, Zhengzhou 450000, China.
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) forms cytoplasmic condensates via liquid-liquid phase separation (LLPS), promoting colon cancer growth. Statins disrupt this process, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is a key driver gene in numerous human cancers.
- Aberrant KRAS signaling contributes significantly to tumor initiation and progression.
Purpose of the Study:
- To elucidate the regulatory mechanisms governing KRAS activity in cancer.
- To investigate the role of liquid-liquid phase separation (LLPS) in KRAS function.
- To identify therapeutic strategies targeting KRAS condensates.
Main Methods:
- Utilized biochemical assays and cell imaging to study KRAS behavior.
- Investigated the role of farnesylation at C185 in KRAS condensate formation.
- Screened FDA-approved drugs for their ability to disrupt KRAS LLPS.
Main Results:
- KRAS forms cytoplasmic condensates through farnesylation-driven LLPS at C185.
- These KRAS condensates enhance Ras-converting enzyme 1 (RCE1) clustering and KRAS plasma membrane translocation, amplifying signaling.
- Condensate formation correlates with advanced colon cancer stages and poor prognosis.
- Statins, notably pitavastatin, inhibit farnesylation, disrupt KRAS LLPS, suppress colon cancer growth, and enhance G12Ci treatment efficacy.
Conclusions:
- LLPS is a critical mechanism regulating KRAS activity and oncogenic potential.
- Targeting KRAS LLPS by inhibiting farnesylation presents a promising therapeutic avenue for KRAS-driven cancers.
- Statins demonstrate potential as adjuvant therapy for colon cancer by modulating KRAS condensate formation.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway

